

Privacy Act Statement. Every registration statement, short form registration statement, supplemental statement, exhibit, amendment, dissemination report, copy of political propaganda or other document or information filed with the Attorney General under this act is a public record open to public examination, inspection and copying during the posted business hours of the Registration Unit in Washington, D.C. One copy is automatically provided to the Secretary of State pursuant to Section 6(b) of the Act, and copies of such documents are routinely made available to other agencies, departments and Congress pursuant to Section 6(c) of the Act. Finally, the Attorney General transmits an annual report to the Congress on the Administration of the Act which lists the names of all agents and the nature, sources and content of the political propaganda disseminated or distributed by them. This report is available to the public.

Public Reporting Burden. Public reporting burden for this collection of information is estimated to average .49 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Chief, Registration Unit, Criminal Division, U.S. Department of Justice, Washington, D.C. 20530; and to the Office of Information and Regulatory Affairs, Office of Management and Budget, Washington, D.C. 20503.

*Furnish this exhibit for EACH foreign principal listed in an initial statement  
and for EACH additional foreign principal acquired subsequently.*

1. Name and address of registrant Professor Dr. Donald Kaiser CH 4070 Basel, Switzerland		2. Registration No. <b>5107</b>
3. Name of foreign principal F.Hoffmann-La Roche Ltd	4. Principal address of foreign principal CH 4070 Basel, Switzerland	

5. Indicate whether your foreign principal is one of the following type:

- Foreign government
- Foreign political party
- Foreign or  domestic organization: If either, check one of the following:
  - Partnership
  - Corporation
  - Association
  - Committee
  - Voluntary group
  - Other (specify) \_\_\_\_\_
- Individual—State his nationality \_\_\_\_\_

6. If the foreign principal is a foreign government, state:

- a) Branch or agency represented by the registrant.
- b) Name and title of official with whom registrant deals. **N/A**

7. If the foreign principal is a foreign political party, state:

- a) Principal address
- b) Name and title of official with whom registrant deals. **N/A**
- c) Principal aim

RECEIVED  
DEPT. OF JUSTICE  
CRIMINAL DIVISION  
96 APR 30 P4:29

8. If the foreign principal is not a foreign government or a foreign political party,

a) State the nature of the business or activity of this foreign principal

The foreign principal is a research-based multinational pharmaceutical company.

b) Is this foreign principal

Owned by a foreign government, foreign political party, or other foreign principal ..... Yes  No

Directed by a foreign government, foreign political party, or other foreign principal..... Yes  No

Controlled by a foreign government, foreign political party, or other foreign principal ..... Yes  No

Financed by a foreign government, foreign political party, or other foreign principal..... Yes  No

Subsidized in whole by a foreign government, foreign political party, or other foreign principal..... Yes  No


Subsidized in part by a foreign government, foreign political party, or other foreign principal..... Yes  No

9. Explain fully all items answered "Yes" in Item 8(b). (If additional space is needed, a full insert page may be used.)

N/A

10. If the foreign principal is an organization and is not owned or controlled by a foreign government, foreign political party or other foreign principal, state who owns and controls it.

The foreign principal is privately held through Roche Holding Ltd located in Basel, Switzerland.

Date of Exhibit A	Name and Title	Signature
April 25, 1996	Professor Dr. Donald Kaiser Head,	
Global Biometrics		

**INSTRUCTIONS:** A registrant must furnish as an Exhibit B copies of each written agreement and the terms and conditions of each oral agreement with his foreign principal, including all modifications of such agreements; or, where no contract exists, a full statement of all the circumstances by reason of which the registrant is acting as an agent of a foreign principal. This form shall be filed in triplicate for each foreign principal named in the registration statement and must be signed by or on behalf of the registrant.

**Privacy Act Statement.** Every registration statement, short form registration statement, supplemental statement, exhibit, amendment, dissemination report, copy of political propaganda or other document or information filed with the Attorney General under this act is a public record open to public examination, inspection and copying during the posted business hours of the Registration Unit in Washington, D.C. One copy is automatically provided to the Secretary of State pursuant to Section 6(b) of the Act, and copies of such documents are routinely made available to other agencies, departments and Congress pursuant to Section 6(c) of the Act. Finally, the Attorney General transmits an annual report to the Congress on the Administration of the Act which lists the names of all agents and the nature, sources and content of the political propaganda disseminated or distributed by them. This report is available to the public.

**Public Reporting Burden.** Public reporting burden for this collection of information is estimated to average .33 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Chief, Registration Unit, Criminal Division, U.S. Department of Justice, Washington, D.C. 20530; and to the Office of Information and Regulatory Affairs, Office of Management and Budget, Washington, D.C. 20503.

Name of Registrant	Name of Foreign Principal
Professor Dr. Donald Kaiser	F.Hoffmann-La Roche Ltd

Check Appropriate Boxes:

- 1.  The agreement between the registrant and the above-named foreign principal is a formal written contract. If this box is checked, attach three copies of the contract to this exhibit.
- 2.  There is no formal written contract between the registrant and foreign principal. The agreement with the above-named foreign principal has resulted from an exchange of correspondence. If this box is checked, attach three copies of all pertinent correspondence, including a copy of any initial proposal which has been adopted by reference in such correspondence.
- 3.  The agreement or understanding between the registrant and the foreign principal is the result of neither a formal written contract nor an exchange of correspondence between the parties. If this box is checked, give a complete description below of the terms and conditions of the oral agreement or understanding, its duration, the fees and the expenses, if any, to be received.

Advising the foreign principal on the status of legislation and/or regulations in the United States that may have an effect on the products and services of the foreign principal. The registrant is a salaried employee of the foreign principal and will receive no additional compensation for these activities. The registrant is reimbursed for travel expenses incurred in connection with these activities.

- 4. Describe fully the nature and method of performance of the above indicated agreement or understanding.

Advising the foreign principal on the status of legislation and/or regulations in the United States that may have an effect on the products and services of the foreign principal and representing the foreign principal with respect to such legislation and/or regulations, and related matters.

RECEIVED  
 DEPT. OF JUSTICE  
 CRIMINAL DIVISION  
 APR 30 1993  
 PA 29


5. Describe fully the activities the registrant engages in or proposes to engage in on behalf of the above foreign principal.

Expression of the views of the foreign principal with respect to legislation and/or regulations in the United States which may affect the products and services of the foreign principal before members of U.S. Congress, Congressional staff, Executive Branch personnel, other government agency officials, trade associations and possibly journalists.

6. Will the activities on behalf of the above foreign principal include political activities as defined in Section 1(o) of the Act?<sup>1</sup>  
Yes  No

If yes, describe all such political activities indicating, among other things, the relations, interests or policies to be influenced together with the means to be employed to achieve this purpose.

See Attachment 6.

Date of Exhibit B	Name and Title	Signature
April 25, 1996	Professor Dr. Donald Kaiser Head, Global Biometrics	

<sup>1</sup>Political activity as defined in Section 1(o) of the Act means the dissemination of political propaganda and any other activity which the person engaging therein believes will, or which he intends to, prevail upon, indoctrinate, convert, induce, persuade, or in any other way influence any agency or official of the Government of the United States or any section of the public within the United States with reference to formulating, adopting, or changing the domestic or foreign policies of the United States or with reference to the political or public interests, policies, or relations of a government of a foreign country or a foreign political party.

**Registrant: Professor Dr. Donald Kaiser**

**6. Will the activities on behalf of the above foreign principal include political activities as defined in Section 1(o) of the Act?**

**If yes, describe all such political activities, indicating, among other things, the relations, interests or policies to be influenced together with the means to be employed to achieve this purpose.**

Expression of the views of the foreign principal with respect to legislation and/or regulations in the United States which may affect the products and services of the foreign principal before members of U.S. Congress, Congressional Staff, Executive Branch personnel, other government agency officials, trade associations and possibly journalists.

September 13, 1995 - Met with the White House Office of National Drug Control Policy: Robert Wasserman, Chief of Staff; Thomas Brayman, Supply Reduction Staff; and Buck Baley, detailee from the U.S. Coast Guard, and met with the Food and Drug Administration/National Institute on Drug Abuse: Stuart L. Nightingale, Associate Commissioner of FDA for Health Affairs; James R. Cooper, Medical Director, NIDA; and Michael Klein, Nicholas Reuter, Yng-shiuh, FDA/NIDA staff to discuss issues relating to Rohypnol.

September 14, 1995 - Met with Department of State: Ambassador Robert Gelbard, Assistant Secretary for International Narcotics Matters; Evangeline Munroe, International Organizations Staff; and Gene Haslip, Director, DEA Office of Diversion Control, and met with the Drug Enforcement Administration: Terrance Woodworth, Deputy Director, Office of Diversion Control; Michael Moy, Chief, Operations Section; Howard McClain, Chief, Drug and Chemical Evaluation Section; Frank Sapienza, Deputy Chief, Drug and Chemical Evaluation Section; and Kenneth Ronald, Special Assistant to Gene Haislip to discuss issues relating to Rohypnol.

January 25, 1996 - Met with White House Office of National Drug Control Policy: Edward Jurith, General Counsel of ONDCP; Leroy Jones, ONDCP Office of Legislative Affairs; Dwight Vick, White House Domestic Policy Staff; Sarah Vogelsburg, Counselor to HHS Secretary Donna Shalala on Drug Matters; Donald Strange, DEA Liaison to ONDCD; and other ONDCP staff members to discuss issues relating to Rohypnol.

January 26, 1996 - Met with Senator Hatch, Chairman of the Senate Judiciary Committee, met with James O'Gara, Trisha Knight and Michael Ashburn, Senator Hatch's staff members on Senate Judiciary Committee; Christopher Putala and Laura Weintraub, Senator Biden's staff on Senate Judiciary Committee; and John Edgell, member of Congressman Joseph Kennedy's staff, and met with Dan Bryant and Erin Duncan, staff members on the Subcommittee on Crime of the House Judiciary Committee, to discuss issues relating to Rohypnol.

April 22, 1996 - Met with Michael Ashburn, Senator Hatch staff member on Senate Judiciary Committee; with Bill Olson, Staff Director of U.S. Senate Caucus on International Narcotics Control; with Jon Garcia, Legislative Assistant for Congresswoman Seastrand; with Sonia Vasquez, Legislative Assistant for Congressman Solomon P. Ortiz; with Michelle Grabda, Judiciary Legislative Assistant for Congressman James T. Walsh; and with Joab Lesesne, Legislative Counsel in Senator Hollings' office to discuss issues relating to Rohypnol.

RECEIVED  
DEPT. OF JUSTICE  
CRIMINAL DIVISION  
APR 30 P 4 29